Posted inClinical Updates Hematology-Oncology news Specialties

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis

A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and combination treatment strategies.
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Posted inClinical Updates Hematology-Oncology Specialties

Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study

Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the primary efficacy endpoint was not met in this phase 2 trial.
Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial
Posted inClinical Updates Hematology-Oncology Specialties

Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial

A pivotal multicenter randomized trial demonstrates that oral Realgar-Indigo naturalis formula (RIF) combined with ATRA is non-inferior to arsenic trioxide (ATO) plus ATRA, providing a simplified consolidation regimen for non-high-risk APL with excellent 2-year disease-free survival and manageable toxicity.
APOLLO Trial Highlights Superior Efficacy of Arsenic Trioxide Plus ATRA in High-Risk Acute Promyelocytic Leukemia
Posted inHematology-Oncology Specialties

APOLLO Trial Highlights Superior Efficacy of Arsenic Trioxide Plus ATRA in High-Risk Acute Promyelocytic Leukemia

The phase III APOLLO trial demonstrates that arsenic trioxide combined with all-trans retinoic acid (ATRA) plus low-dose idarubicin improves event-free survival and reduces relapse rates compared to standard ATRA plus anthracycline chemotherapy in high-risk APL patients, with fewer serious adverse events.